A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
NCT04994002 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2022-03-22
Summary
The primary objective of this study is to evaluate the safety and tolerability of CERC-006 in adults (aged 18-31 years) with active, moderate to severe complex lymphatic malformations.
Conditions
- Lymphatic Malformation
Interventions
- DRUG
-
CERC-006
Oral solution
Sponsors & Collaborators
-
Avalo Therapeutics, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 31 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-09-03
- Primary Completion
- 2022-06-30
- Completion
- 2022-06-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
NCT03533673 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
NCT00975819 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
NCT01811667 ·Status: COMPLETED ·Phase: PHASE3
-
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
NCT02618512 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
NCT06673290 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)
NCT06948019 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
NCT04999059 ·Status: TERMINATED
-
Weekly Sirolimus Therapy
NCT04861064 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
NCT05200104 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
NCT06789913 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT02324049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Camoteskimab in Participants With Still's Disease
NCT04752371 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
NCT04998812 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560 ·Status: RECRUITING
-
A Study of RG1662 in Individuals With Down Syndrome
NCT01436955 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
NCT02638389 ·Status: RECRUITING ·Phase: PHASE3
-
Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions
NCT04172922 ·Status: TERMINATED ·Phase: PHASE1
-
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
NCT06181136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
NCT00688597 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT06508021 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
NCT05130450 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
NCT05630066 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
NCT02603562 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
NCT05902598 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
NCT03802799 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3